Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Update

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the recipient of a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 13,496 shares, a decrease of 47.6% from the January 15th total of 25,740 shares. Based on an average trading volume of 103,809 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.4% of the shares of the stock are short sold. Approximately 0.4% of the shares of the stock are short sold. Based on an average trading volume of 103,809 shares, the days-to-cover ratio is currently 0.1 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research report on Wednesday, January 28th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Kiora Pharmaceuticals currently has an average rating of “Hold” and an average price target of $10.00.

Institutional Trading of Kiora Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in KPRX. Two Sigma Investments LP purchased a new stake in shares of Kiora Pharmaceuticals in the 3rd quarter worth about $33,000. Renaissance Technologies LLC boosted its holdings in shares of Kiora Pharmaceuticals by 71.0% in the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after buying an additional 8,800 shares during the last quarter. Citadel Advisors LLC bought a new stake in Kiora Pharmaceuticals during the 3rd quarter worth approximately $125,000. Alyeska Investment Group L.P. purchased a new stake in Kiora Pharmaceuticals in the 4th quarter worth $152,000. Finally, DRW Securities LLC grew its position in Kiora Pharmaceuticals by 199.2% in the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock worth $217,000 after acquiring an additional 73,417 shares in the last quarter. 76.97% of the stock is currently owned by hedge funds and other institutional investors.

Kiora Pharmaceuticals Price Performance

KPRX remained flat at $2.08 during midday trading on Friday. The company’s stock had a trading volume of 8,280 shares, compared to its average volume of 66,299. Kiora Pharmaceuticals has a 52-week low of $1.76 and a 52-week high of $4.18. The business has a fifty day moving average price of $2.13 and a 200 day moving average price of $2.37. The firm has a market capitalization of $7.65 million, a price-to-earnings ratio of -1.00 and a beta of -0.82.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.